DMRA

News

globenewswire.comDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 1

seekingalpha.comDamora Therapeutics: Well-Funded Moonshot For CALR Mutationsseekingalpha.comMay 27

globenewswire.comDamora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlightsglobenewswire.comMay 12

globenewswire.comDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comMay 1

defenseworld.netDamora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Consensus Recommendation of “Moderate Buy” by Analystsdefenseworld.netApr 23

Trade DMRA

About Damora Therapeutics, Inc.

Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.

CEO: Jennifer A. Jarrett
IPO Date: Mar 10, 2026

Market Data

Open: $21.71
High: $22.33
Low: $21.04
Volume: 1.2M
Avg Volume: 328.6K
52W High: $38.33
52W Low: $2.45

Valuation

Market Cap: $1.3B
Enterprise Value: $775M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-6.7M
Revenue: $0
Net Income: $-210M
Cash: $258M
Debt: $68k

Events

EarningsAug 5

EPS est. -0.43633